Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 23:16:20420986251360915.
doi: 10.1177/20420986251360915. eCollection 2025.

Mind the gap between therapeutic drug monitoring laboratories and clinicians-bridging with clinical pharmacologists' comprehensive assessment and interview

Ivana Mikačić  1   2   3 , Hrvačić Martina  2 , Barišić Dunja  4   2 , Majstorović Barać Karolina  4   2 , Kurtov Marija  4   2 , Šprem Dragica  4   2
Affiliations

Mind the gap between therapeutic drug monitoring laboratories and clinicians-bridging with clinical pharmacologists' comprehensive assessment and interview

Ivana Mikačić et al. Ther Adv Drug Saf. .
No abstract available

Keywords: clinical pharmacologist; comprehensive clinical interview; drug interactions; good clinical practice; therapeutic drug monitoring.

PubMed Disclaimer

Figures

“In patient-centered care, the attending physician monitors drug treatment through therapy, where the patient consultation with the clinical pharmacologist/clinician-pharmacist is essential. The individual, drug, and disease aspects are considered, with analysis by the clinical laboratory followed by a written report summarizing results for the physician's final interpretation.”
Figure 1.
The patient-centered approach is one in which the attending physician sends the patient for therapeutic drug monitoring. The patient is interviewed by the clinical pharmacologist/clinical pharmacist. All important aspects are taken into account, including those related to the individual, the drug, and the disease. This is a critical step in ensuring comprehensive individual assessment. The patient is then forwarded to the clinical laboratory to proceed with the analysis and, when done, again sent to the clinical pharmacologist to write the final report. This report includes all relevant information summarized together to serve as a significant aid in the interpretation by the attending physician.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Orme M, Sjöqvist F, Birkett D, et al. Clinical pharmacology in research, teaching, and health care. Basic Clin Pharmacol Toxicol 2010; 107(1): 531–559. - PubMed
    1. Doherty RB, Crowley RA; Health and Public Policy Committee of the American College of Physicians. Principles supporting dynamic clinical care teams: an American College of Physicians position paper. Ann Intern Med 2013; 159(9): 620–626. - PubMed
    1. Shipkova M, Christians U. Improving therapeutic decisions: pharmacodynamic monitoring as an integral part of therapeutic drug monitoring. Ther Drug Monit 2019; 41(2): 111–114. - PMC - PubMed
    1. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med 2009; 24(1): 1–10. - PMC - PubMed
    1. Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 2016; 13(11): e1002160. - PMC - PubMed

LinkOut - more resources